Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EuroEyes International Eye Clinic Limited ( (HK:1846) ) has provided an update.
EuroEyes International Eye Clinic Limited has issued a clarification and completion announcement regarding its previously disclosed acquisitions of ophthalmic assets in Switzerland and the United Kingdom via its subsidiaries. The company detailed the shareholder structure and ownership of Betterview Swiss and its UK subsidiary, confirming that Betterview Swiss has 44 shareholders with no single shareholder controlling more than one-third of its equity. It also clarified that the Swiss consideration shares to be issued as part of the transaction will be distributed to these 44 shareholders in proportion to their holdings, and that EuroEyes Swiss will grant 4.5% equity stakes each to managers David Holenstein and Ulrich Harmuth as compensation to secure their continued leadership of the Swiss operations. The post-completion shareholding structure of EuroEyes Swiss will see the listed parent own 79% of the ordinary shares, while minority shareholders, including key managers, will hold both ordinary and non-voting shares, aligning management incentives with the performance of the acquired Swiss assets. The company also corrected a typographical error in the description of its Swiss asset base, noting that one of the refractive surgery clinics is located in Basel rather than Lucerne, thereby providing investors with more accurate information about the geographic composition of its Swiss clinic network.
The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.
More about EuroEyes International Eye Clinic Limited
EuroEyes International Eye Clinic Limited is a specialist ophthalmic healthcare group operating eye clinics, focused on refractive surgery and related eye treatments. The company expands and manages clinical assets through subsidiaries across multiple European markets, including Switzerland and the United Kingdom.
Average Trading Volume: 91,400
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$914.6M
See more data about 1846 stock on TipRanks’ Stock Analysis page.